RAPT Therapeutics (RAPT) Price & Analysis

Compare

377 Followers

RAPT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.67 - $26.56

Previous CloseN/A

Volume421.15K

Average Volume (3M)120.67K

Market Cap

$179.93M

Enterprise Value$49.82M

Total Cash (Recent Filing)$168.95M

Total Debt (Recent Filing)$3.16M

Price to Earnings (P/E)―

Beta1.76

Next Earnings

Nov 06, 2025

EPS Estimate

-1.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding16,537,794

10 Day Avg. Volume172,822

30 Day Avg. Volume120,669

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.28

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-249.08

Enterprise Value/Ebitda-0.45

Forecast

1Y Price Target

$23.67

Price Target Upside109.84% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsInitial data from Jemincare's RPT904 CSU and asthma trials expected to be major catalysts.

Financial PositionThe company ended 2Q with a cash position of $168.9MM, providing a solid financial footing.

Market OpportunityFood Allergy is a massive market opportunity, and even an incremental share can result in a potentially large blockbuster opportunity for the company.

Bears Say

Potential SetbacksA setback in the Jemincare’s phase 2 study in CSU and asthma could call into question the potential success of RPT904.

Price Target AdjustmentThe price target has been adjusted from $51 to $38, reflecting updated model assumptions including the removal of the oncology program.

Visibility ChallengesGiven the prior pipeline setbacks for the company, RPT904 remains somewhat under-the-radar and may need company-sponsored data to increase visibility of the asset.

RAPT Therapeutics News

Rapt Therapeutics price target raised to $9 from $8 at UBS

UBS analyst Eliana Merle raised the firm’s price target on Rapt Therapeutics (RAPT) to $9 from $8 and...

16d ago

RAPT

Rapt Therapeutics price target lowered to $38 from $51 at Wells Fargo

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Rapt Therapeutics (RAPT) to $38 from $51...

20d ago

RAPT

Rapt Therapeutics reports Q2 EPS (65c), consensus (65c)

“The first half of 2025 has been productive, with several key achievements setting the stage for important catalysts...

21d ago

RAPT

Rapt Therapeutics target adjusted to $24 from $3 at Clear Street

Clear Street adjusted the firm’s price target on Rapt Therapeutics (RAPT) to $24 from $3 and keeps a...

22d ago

RAPT

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

JPMorgan upgraded Rapt Therapeutics (RAPT) to Neutral from Underweight with a $14 price target The firm says the...

29d ago

RAPT

Promising Potential of RAPT Therapeutics’ RPT904 Drives Buy Rating

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on RAPT Therapeutics on August 7 and set a...

17d ago

RAPT

RAPT Therapeutics: Anticipated Growth Driven by Strategic Partnerships and Promising Clinical Developments

Analyst Yanan Zhu of Wells Fargo maintained a Buy rating on RAPT Therapeutics, reducing the price target to...

20d ago

RAPT

Rapt Therapeutics’ Reverse Stock Split: Potential Pitfalls and Market Challenges

Rapt Therapeutics Inc (RAPT) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rapt...

21d ago

RAPT

RAPT Therapeutics Reports Q2 2025 Financial Results

Rapt Therapeutics Inc ( ($RAPT) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

RAPT

RAPT Therapeutics’ RPT904: A Promising Catalyst with Competitive Edge in the Anti-IgE Market

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on RAPT Therapeutics, with...

21d ago

RAPT

LifeSci starts Rapt Therapeutics at Outperform on potential for lead asset

As previously reported, LifeSci Capital initiated coverage of Rapt Therapeutics (RAPT) with an Outperform rating and $31 price...

1M ago

RAPT

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Rapt Therapeutics (RAPT) with an Outperform rating and $31 price target Published first...

1M ago

RAPT

RAPT Therapeutics: Promising Growth Potential with Innovative Immunology Developments

RAPT Therapeutics (RAPT) has received a new Buy rating, initiated by LifeSci Capital analyst, Sam Slutsky. Sam Slutsky’s...

1M ago

RAPT

RAPT Therapeutics trading resumes

09:44 EDT RAPT Therapeutics (RAPT) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

1M ago

RAPT

RAPT FAQ

What was RAPT Therapeutics’s price range in the past 12 months?

RAPT Therapeutics lowest stock price was $5.67 and its highest was $26.56 in the past 12 months.

What is RAPT Therapeutics’s market cap?

RAPT Therapeutics’s market cap is $179.93M.

When is RAPT Therapeutics’s upcoming earnings report date?

RAPT Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 70 days.

How were RAPT Therapeutics’s earnings last quarter?

RAPT Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.711 by $0.061.

Is RAPT Therapeutics overvalued?

According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does RAPT Therapeutics pay dividends?

RAPT Therapeutics does not currently pay dividends.

What is RAPT Therapeutics’s EPS estimate?

RAPT Therapeutics’s EPS estimate is -1.02.

How many shares outstanding does RAPT Therapeutics have?

RAPT Therapeutics has 16,537,794 shares outstanding.

What happened to RAPT Therapeutics’s price movement after its last earnings report?

RAPT Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.711. Following the earnings report the stock price went up 2.603%.

Which hedge fund is a major shareholder of RAPT Therapeutics?

Currently, no hedge funds are holding shares in RAPT

RAPT Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-77.83%

Trailing 12-Months

Asset Growth

40.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

RAPT Therapeutics

RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for oncology and inflammatory diseases. Based in the United States, RAPT employs its proprietary drug discovery and development engine to create highly selective oral therapies aimed at key points in the immune system. The company’s lead product candidates include RPT193 and FLX475, which are designed to target specific pathways involved in the regulation of immune cells.

RAPT Therapeutics (RAPT) Earnings & Revenues

Historic Earnings Reports

RAPT Stock 12 Month Forecast

Average Price Target

$23.67

▲(109.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","21":"$21","36":"$36","51":"$51","66":"$66"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,21,36,51,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.49,12.606153846153846,14.722307692307691,16.838461538461537,18.954615384615384,21.07076923076923,23.186923076923073,25.303076923076922,27.419230769230765,29.535384615384615,31.651538461538458,33.76769230769231,35.88384615384615,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.49,11.503846153846155,12.517692307692307,13.531538461538462,14.545384615384616,15.559230769230771,16.573076923076925,17.586923076923078,18.60076923076923,19.614615384615387,20.628461538461544,21.642307692307696,22.65615384615385,{"y":23.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.49,10.375384615384615,10.260769230769231,10.146153846153846,10.031538461538462,9.916923076923077,9.802307692307693,9.687692307692307,9.573076923076924,9.458461538461538,9.343846153846155,9.22923076923077,9.114615384615384,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.44,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.04,"date":1719792000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >